Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TLSI 
TriSalus Life Sciences Inc. (TLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: TLSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.36
1 Year Target Price $11.36
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.52% | Avg. Invested days 53 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 218.92M USD | Price to earnings Ratio - | 1Y Target Price 11.36 |
Price to earnings Ratio - | 1Y Target Price 11.36 | ||
Volume (30-day avg) 8 | Beta 0.47 | 52 Weeks Range 3.42 - 5.88 | Updated Date 11/6/2025 |
52 Weeks Range 3.42 - 5.88 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -86.61% | Operating Margin (TTM) -65.39% |
Management Effectiveness
Return on Assets (TTM) -52.51% | Return on Equity (TTM) -496.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 232572101 | Price to Sales(TTM) 6.08 |
Enterprise Value 232572101 | Price to Sales(TTM) 6.08 | ||
Enterprise Value to Revenue 6.46 | Enterprise Value to EBITDA -5.96 | Shares Outstanding 49867279 | Shares Floating 39485909 |
Shares Outstanding 49867279 | Shares Floating 39485909 | ||
Percent Insiders 42.49 | Percent Institutions 17.45 |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a commercial-stage oncology company integrating drug-delivery technology and immunotherapy to treat liver and pancreatic tumors. Founded in 2009, the company focuses on improving outcomes for patients with these challenging cancers through innovative locoregional therapies.
Core Business Areas
- TriNav Microcatheters: These microcatheters are designed for targeted delivery of therapeutics to tumors in the liver and pancreas.
- Pressure-Enabled Drug Delivery (PEDD): PEDD uses pressure to overcome intratumoral pressure barriers, enhancing drug penetration and distribution within the tumor microenvironment.
- Clinical Research and Development: TriSalus conducts clinical trials to evaluate the safety and efficacy of its therapies and expand its pipeline.
Leadership and Structure
Mary Szela serves as the Chief Executive Officer. The company has a board of directors and a leadership team overseeing research and development, clinical operations, and commercial activities.
Top Products and Market Share
Key Offerings
- TriNav Microcatheter: A device designed for pressure-enabled drug delivery to liver tumors. It is a key tool in their PEDD approach. No specific market share data is readily available. Competitors in the microcatheter market include Boston Scientific (BSX), Medtronic (MDT), and Terumo (OTCMKTS: TRUMY).
- MATCH-BT Trial: A clinical trial focused on patients with perihilar cholangiocarcinoma. Revenue isn't directly attributable, but reflects the future potential of PEDD in cancer therapy. No specific market share data is readily available. Competitors exploring cholangiocarcinoma treatments include QED Therapeutics and others focused on targeted therapies.
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet needs, rapid innovation, and significant investment. Locoregional therapies for liver and pancreatic cancer are a growing segment within this market.
Positioning
TriSalus is positioned as a leader in pressure-enabled drug delivery for liver and pancreatic tumors. Its competitive advantage lies in its patented PEDD technology and focus on overcoming intratumoral pressure barriers.
Total Addressable Market (TAM)
The global liver cancer therapeutics market is estimated to reach billions of dollars, positioning TriSalus with significant TAM potential in liver cancer therapy. Pancreatic cancer TAM is also in the billions of dollars. PEDD aims to improve current cancer treatment options which can potentially capture a significant share of the TAM with more clinical evidence.
Upturn SWOT Analysis
Strengths
- Proprietary PEDD technology
- Focus on unmet needs in liver and pancreatic cancer
- Experienced leadership team
- Early commercial traction
Weaknesses
- Limited commercial history
- Reliance on clinical trial success
- High R&D expenses
- Potential need for additional funding
Opportunities
- Expansion of PEDD technology to other tumor types
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Increased adoption of locoregional therapies
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BSX
- MDT
- Varian Medical Systems (Siemens Healthineers)
Competitive Landscape
TriSalus competes with established medical device companies in the microcatheter and drug delivery space. Its PEDD technology offers a unique approach, but competition is intense.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical development and product launch.
Future Projections: Future growth is projected based on clinical trial success, market adoption of PEDD technology, and potential partnerships.
Recent Initiatives: Recent initiatives include expanding clinical trials, increasing commercial outreach, and exploring partnerships.
Summary
TriSalus Life Sciences is an early-stage company with innovative PEDD technology targeting unmet needs in liver and pancreatic cancer. Its proprietary technology and focus on difficult-to-treat tumors provide competitive advantages. Success depends heavily on clinical trial outcomes and market adoption of PEDD. Competition from established medical device companies and potential regulatory hurdles pose significant challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-10 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.